[Recombinant factor VIIa for treatment of postpartum hemorrhage due to uterine atony].
BACKGROUND
Obstetric hemorrhage is a life-threatening situation for every mother and child. NovoSeven is a recombinant, activated factor VII which may be useful in the treatment of uncontrollable hemorrhage. It accelerates hemostasis by direct activation of the factor X.


METHODS
The author presents her own experience with administration of NovoSeven at the Intensive Care Unit, Medical University Szczecin in the treatment of bleedings after standard methods failure. NovoSeven was given to patients in postpartum hemorrhage due to uterine atony who did not present any signs of haemostatic disorders.


RESULTS
In all presented cases, bleeding symptoms abated and hemodynamic stabilization was obtained shortly after the drug administration.


CONCLUSIONS
NovoSeven is a very effective agent in the treatment of postpartum hemorrhage.
Michalska-Krzanowska
Grazyna
G
Oddział Intensywnej Terapii SPSK Nr1 PAM, Szczecin-Police. grazyna195@op.pl
D000328:Adult; D003029:Coagulants / Q000627:therapeutic use*; D004636:Emergency Service, Hospital / Q000458:organization & administration; D004638:Emergency Treatment / Q000379:methods*; D015942:Factor VIIa / Q000627:therapeutic use*; D005260:Female; D006487:Hemostasis; D006801:Humans; D011044:Poland; D006473:Postpartum Hemorrhage / Q000188:drug therapy* / Q000209:etiology / Q000517:prevention & control; D011247:Pregnancy; D011994:Recombinant Proteins / Q000627:therapeutic use; D012771:Shock, Hemorrhagic / Q000188:drug therapy; D016896:Treatment Outcome; D014593:Uterine Inertia; D055815:Young Adult
D003029:Coagulants; D011994:Recombinant Proteins; C103587:recombinant FVIIa; D015942:Factor VIIa